ClearPoint Neuro (CLPT) Liabilities and Shareholders Equity (2018 - 2025)
ClearPoint Neuro's Liabilities and Shareholders Equity history spans 13 years, with the latest figure at $60.4 million for Q3 2025.
- For Q3 2025, Liabilities and Shareholders Equity rose 50.17% year-over-year to $60.4 million; the TTM value through Sep 2025 reached $192.5 million, up 1.81%, while the annual FY2024 figure was $39.2 million, 8.14% down from the prior year.
- Liabilities and Shareholders Equity for Q3 2025 was $60.4 million at ClearPoint Neuro, down from $62.9 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $74.3 million in Q1 2021 and bottomed at $30.1 million in Q1 2025.
- The 5-year median for Liabilities and Shareholders Equity is $55.5 million (2022), against an average of $54.7 million.
- The largest annual shift saw Liabilities and Shareholders Equity surged 214.87% in 2021 before it tumbled 43.94% in 2025.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $65.6 million in 2021, then decreased by 15.39% to $55.5 million in 2022, then fell by 23.12% to $42.7 million in 2023, then dropped by 8.14% to $39.2 million in 2024, then soared by 54.02% to $60.4 million in 2025.
- Per Business Quant, the three most recent readings for CLPT's Liabilities and Shareholders Equity are $60.4 million (Q3 2025), $62.9 million (Q2 2025), and $30.1 million (Q1 2025).